Financial Data and Key Metrics Changes - Total fourth quarter revenue reached $11.3 million, representing a 37% year-over-year growth and a quarterly record, exceeding previous guidance [9][19] - Product revenue increased by 78% in Q4, driven by strong system placements, while consumable revenue grew by 11% [11][19] - Recurring revenue increased by 15% for the full year, accounting for 53% of total revenue, indicating strong utilization of installed systems [11] Business Line Data and Key Metrics Changes - The company placed 16 Growth Direct systems in Q4, a record number, bringing the total to 190 systems globally, with 155 fully validated [9][19] - Service revenue was $2 million in Q4, consistent with guidance, but lower than $3 million in Q4 2024 due to timing of validations [20] Market Data and Key Metrics Changes - The partnership with MilliporeSigma is expected to contribute significantly to system placements in 2026, with ongoing training and demo labs established across Europe and Asia [12][15] - The company is seeing strong demand from both principal manufacturers and CDMOs, with significant orders from Amgen and Samsung Biologics [10][15] Company Strategy and Development Direction - The company aims to accelerate system placements, expand gross margins, innovate new products, and manage cash prudently [13][30] - A new cloud-native software platform is expected to be released in the second half of 2026, enhancing customer experience and providing AI-driven analytics [17][68] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a full-year 2026 revenue guidance of $37 million to $41 million, with expectations for gross margin expansion to approximately 20% [18][29] - The company anticipates strong tailwinds from increased automation adoption and a focus on data integrity in the pharmaceutical industry [16] Other Important Information - Fourth quarter gross margin was impacted by inventory-related charges, but significant progress was made in reducing product costs and improving manufacturing efficiencies [11][21] - The company ended the year with $39 million in cash and investments, aligning with guidance [24] Q&A Session Summary Question: What is being done to reduce the gap between placed and validated systems? - Management indicated that timing variations affect the validation process and expects to see the gap decrease as they work with customers [32][34] Question: What percentage of placed systems are within CDMOs, and how is that space evolving? - Management noted a strong value proposition for CDMOs and highlighted significant orders from both CDMOs and principal manufacturers [35][37] Question: What are the key drivers for achieving the 20% gross margin target for 2026? - Key drivers include locked-in product cost reductions and expected increases in service revenues as validations progress [41][43] Question: How will the next-gen cloud-native software platform be integrated into devices? - The platform will be a complete rewrite of the application software, providing easier integration and potential future revenue from cloud services [67][68] Question: What moves are being made to drive consumable cost reductions? - The company is working with various vendors to achieve significant cost reductions, which will benefit gross margins in 2026 [72][74]

Rapid Micro Biosystems (NasdaqCM:RPID) Q4 2025 Earnings call March 12, 2026 08:30 AM ET Company ParticipantsAnn-Kate Heller - Senior Vice President of Investor RelationsDan Arias - Managing DirectorMichael Beaulieu - VP of Investor Relations and Corporate CommunicationsRobert Spignesi - CEO and PresidentSean Wirtjes - CFOConference Call ParticipantsBrendan Smith - Tools/Dx AnalystThomas Flaten - Senior Research AnalystOperatorGood day, and thank you for standing by.Welcome to the Rapid Micro Biosystems Q4 a ...

Summary of Rapid Micro Biosystems FY Conference Call Company Overview - **Company**: Rapid Micro Biosystems (NasdaqCM: RPID) - **Industry**: Pharmaceutical Quality Control - **Focus**: Automation of microbial quality control processes in pharmaceutical manufacturing, addressing the outdated methods that have not changed significantly in over a century [7][19] Key Financial Highlights - **2025 Revenue**: Approximately $34 million, representing a 20% growth year-over-year [8] - **Recurring Revenue**: Strong double-digit growth throughout the year, with a notable increase in placements and validation of systems [13][15] - **Record Quarterly Revenue**: Achieved in Q4 with a growth rate of 37% [15] - **Term Loan**: Secured a $45 million term loan from Trinity Capital to strengthen the balance sheet [14] Business Model and Technology - **Growth Direct System**: The only fully automated high-throughput microbial quality control system, designed to replace traditional Petri dish methods [24][25] - **Validation Process**: 190 systems placed globally, with 155 validated, marking a critical milestone for generating recurring revenue [10] - **Recurring Revenue Stream**: Generated from consumables and service contracts post-validation [9][26] Market Position and Customer Base - **Customer Base**: 75% of the top 20 global pharmaceutical companies are customers, indicating strong market penetration [11][32] - **Market Size**: Estimated at $5 billion for recurring revenue and an additional $5 billion for system opportunities [29] - **Growth Strategy**: Focus on a "land and expand" approach, acquiring customers and expanding through additional systems and applications [30][31] Strategic Partnerships - **Merck MilliporeSigma Partnership**: Aims to accelerate growth through ecosystem placements, improve gross margins, and drive innovation [15][16] - **Distribution Agreement**: MilliporeSigma has a purchase commitment for the first two years, enhancing sales capabilities [16] Industry Trends and Future Outlook - **Onshoring Trend**: Increasing interest in automation in new sites, particularly in North America, driven by regulatory pressures and cost considerations [30][41] - **AI Integration**: Future software updates will leverage AI to analyze data from Growth Direct systems, providing insights into quality control and operational efficiency [55] Financial Performance and Projections - **Compounded Annual Growth Rate**: 25% over the past several years, driven by organic sales and growth strategies [36] - **Gross Margin Improvement**: 60 percentage point improvement, with expectations for continued growth due to operational efficiencies and partnerships [37] - **Positioning for Success**: Strong customer base, innovative product offerings, and a focus on automation position the company well for future growth [38] Conclusion - **Long-term Value Creation**: The company is focused on delivering sustainable shareholder value through its innovative solutions in the pharmaceutical quality control market, addressing significant industry needs and regulatory pressures [39][40]